ISTANBUL—Age does not affect clinical outcomes in sorafenib-treated patients with advanced renal cell carcinoma (RCC), researchers announced here at the 31st congress of the European Society for Medical Oncology. In fact, their data, from a phase III trial of sorafenib that enrolled 903 patients with advanced RCC who had failed one prior systemic treatment, show that the oral multi-kinase inhibitor provides similar clinical benefit and a low toxicity profile, irrespective of age.
The magnitude of improvement in progression-free survival was similar in patients younger than 65 years of age (23.9 weeks for sorafenib versus 12 weeks for placebo) and patients aged 65 years and older (25.9 weeks for sorafenib versus 11.9 weeks for placebo). “Thus, sorafenib doubled progression-free survival compared with placebo in older and younger patients,” said investigator Tim Eisen, PhD, FRCP, professor of medical oncology at Cambridge, UK.
Drug-related adverse events, such as rash and desquamation, diarrhea, hand-foot skin reaction, alopecia, fatigue, and pruritus, occurred with similar frequency in the two age groups.
Overall, the findings support the use of sorafenib in older patients with advanced RCC, Dr. Eisen said.